Skip to main
INKT

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics is expected to have a positive outlook as the company has successfully entered into a collaboration with C-Further to further develop and fund their PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers. The company's financials show potential for increased operating expenses in 2026 as they initiate phase 2b/3 trials, but with $13.4M in cash and non-dilutive funding received, the company is well-funded to support their operations until late 2026/early 2027. The inherent advantages of iNKT cell therapies over traditional treatments make MiNK a promising player in the biopharmaceutical industry.

Bears say

MiNK Therapeutics is in the early stages of its development and is currently focused on initiating a Phase 2 clinical trial for severe pulmonary diseases and GvHD. With no approved therapies currently available and positive survival data in previous studies, the company has low bar for success. However, the expected trial size, funding source, and potential collaboration with ImmunityBio suggest a potential for external capital to be used, which may impact the company's overall financial health.

MiNK Therapeutics (INKT) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Strong Buy based on their latest research and market trends.

According to 1 analysts, MiNK Therapeutics (INKT) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.